TABLE 2

Change from baseline in primary and selected secondary end-points with bosentan and placebo in the Bosentan Effects in Inoperable Forms of Chronic Thromboembolic Pulmonary Hypertension (BENEFiT) study

End-point	Placebo			Bosentan			p-value^#
End-point	Patients	Baseline	Change	Patients	Baseline	Change	p-value^#
Co-primary end-points
6MWD m	73	344.5 (325.2–363.8)	0.8 (–18.1–19.7)	67	340.0 (319.2–360.8)	2.9 (–12.9–18.8)	0.5449
PVR dyn·s·cm^–5	71	787 (708–866)	30 (–25–85)	66	778 (698–857)	–146 (–207– –85)	<0.0001
Selected secondary end-points
NT-proBNP ng·L⁻¹	76	1405		72	1481	–622 (–1018– –225)^¶	0.0034
WHO-FC II/III/IV	80	22/56/2	11.3% moved to lower class; 8.8% moved to higher class	76	22/51/3	14.5% moved to lower class; 2.6% moved to higher class	ns

Data are presented as n or mean (95% confidence interval), unless otherwise stated. 6MWD: 6-min walking distance; PVR: pulmonary vascular resistance; NT-proBNP: N-terminal pro-brain natriuretic peptide; WHO-FC: World Health Organization functional class; ns: nonsignificant. ^#: calculated with the use of stratified Wilcoxon test for the change from baseline and the Wilcoxon rank sum test for treatment effect; ^¶: data for treatment effect, not change from baseline. Data from [41].